- Home
- STTK vs BYFC Comparison
STTK vs BYFC Comparison
Compare STTK & BYFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- BYFC
- Stock Information
- Founded
- STTK 2016
- BYFC 1946
- Country
- STTK United States
- BYFC United States
- Employees
- STTK N/A
- BYFC N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- BYFC Savings Institutions
- Sector
- STTK Health Care
- BYFC Finance
- Exchange
- STTK Nasdaq
- BYFC Nasdaq
- Market Cap
- STTK 54.4M
- BYFC 64.1M
- IPO Year
- STTK 2020
- BYFC 1996
- Fundamental
- Price
- STTK $1.16
- BYFC $7.05
- Analyst Decision
- STTK Hold
- BYFC
- Analyst Count
- STTK 3
- BYFC 0
- Target Price
- STTK $2.00
- BYFC N/A
- AVG Volume (30 Days)
- STTK 332.9K
- BYFC 6.7K
- Earning Date
- STTK 11-14-2024
- BYFC 10-29-2024
- Dividend Yield
- STTK N/A
- BYFC N/A
- EPS Growth
- STTK N/A
- BYFC N/A
- EPS
- STTK N/A
- BYFC 0.28
- Revenue
- STTK $6,435,000.00
- BYFC $35,113,000.00
- Revenue This Year
- STTK $313.04
- BYFC N/A
- Revenue Next Year
- STTK N/A
- BYFC N/A
- P/E Ratio
- STTK N/A
- BYFC $24.70
- Revenue Growth
- STTK 382.75
- BYFC 12.14
- 52 Week Low
- STTK $0.94
- BYFC $4.41
- 52 Week High
- STTK $11.76
- BYFC $7.99
- Technical
- Relative Strength Index (RSI)
- STTK 44.02
- BYFC 54.16
- Support Level
- STTK $1.07
- BYFC $7.01
- Resistance Level
- STTK $1.38
- BYFC $7.24
- Average True Range (ATR)
- STTK 0.12
- BYFC 0.14
- MACD
- STTK 0.01
- BYFC -0.00
- Stochastic Oscillator
- STTK 27.88
- BYFC 60.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.